1. Generics Bulletin

China Sees Flurry Of Activity On Avastin

Innovent’s Biosimilar Bevacizumab Approved As Bio-Thera And Henlius Advance

 
• By Dave Wallace

An approval for Innovent’s bevacizumab biosimilar has been granted in China, while other potential rivals to Avastin in the region have hit development milestones.

Eye_China_Flag
China has seen an approval for one bevacizumab biosimilar, with others in the pipeline • Source: Shutterstock

Innovent Biologics has received approval from China’s National Medical Products Administration for its Byvasda (bevacizumab) biosimilar rival to Avastin.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products